Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
Christian Rolfo(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), María José Serrano(Instituto de Investigación Biosanitaria de Granada), Umberto Malapelle(University of Naples Federico II), José A. Lorente(Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research), Massimo Cristofanilli(Thomas Jefferson University), Ignacio Durán(Instituto de Biomedicina de Sevilla), Eloísa Jantus‐Lewintre(Hospital General Universitario De Valencia), Alessandro Russo(University of Messina), Luis Paz‐Ares(Universidad Complutense de Madrid), Patrick Pauwels(University of Antwerp), Tony Mok(Chinese University of Hong Kong), Juan J. Díaz‐Mochon(Universidad de Granada), Andrés F. Cardona(Universidad El Bosque), Ignacio Gil‐Bazo(Navarre Institute of Health Research), Luis E. Raez(Florida International University)
Cited by 135
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k